Top Tweets for #DualityBio
$BNTX #DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast Cancer https://t.co/dbRXJech2v
BioNTech and DualityBio Score at Phase III with Breast Cancer Therapy
@BioNTech_Group and #DualityBio succeed at Phase III with trastuzumab pamirtecan in patients with metastatic or inoperable HER2 positive breast cancer
#breastcancer #clinicaltrial
https://t.co/y9VKH07WBN
$BNTX and 🇨🇳 #DualityBio announced that the pivotal Phase 3 trial (NCT06265428) which DualityBio is conducting in China to evaluate trastuzumab pamirtecan (BNT323/DB-1303) versus trastuzumab emtansine (T-DM1) in patients with HER2-positive unresectable or metastatic breast cancer who have previously received trastuzumab and a taxane-based chemotherapy met its primary endpoint of progression free survival at a pre-specified interim analysis.https://t.co/6fyKQ9ij6i
Trastuzumab pamirtecan (BNT323/DB-1303) is HER2 ADC. BioNTech licensed certain rights for the drug from DualityBio in 2023.
🇨🇳 #DualityBio registered a Phase 3 clinical trial in China for its #HER2 #ADC BNT323/DB-1303.
The trial compares BNT323/DB-1303 with investigator-selected chemotherapy in patients with previously treated HER2-expressing recurrent endometrial cancer, is the China part of the global multicenter trial Fern-EC-01, registered by BioNTech $BNTX in April.
In April, 2023, DualityBio granted BioNTech ex-Greater China global rights for two ADC drugs, including DB-1303.
DB-1303 is a 3rd-generation HER2 ADC developed using DualityBio’ DITAC platform, using DualityBio’s proprietary topoisomerase inhibitor toxin P1003 and a GGFG linker, with a DAR value of 8.
ESGO2023, DualityBio first reported the data for DB-1303 in advanced/metastatic endometrial cancer.
In Dec 2023, DB-1303 received Breakthrough Therapy Designation from the FDA for the indication of HER2-expressing endometrial cancer.
🇨🇳 #ASCO2025 #DualityBio reported preliminary results form Ph1/2a trial of #DB1310, a #HER3-targeted #ADC, in pts with advanced solid tumors. https://t.co/ML8gdUR6cz
DB-1310 is a novel ADC comprised of a humanized anti-HER3 IgG1 monoclonal antibody, cleavable peptide linker, and DNA topoisomerase I inhibitor.
The unconfirmed ORR was 25.5% (95% CI, 17.63, 34.65) across all tumor types and 35.7% (95% CI, 21.55, 51.97) in EGFRm NSCLC. Median PFS was 5.4 months overall and 7.0 months for EGFRm NSCLC.
🇨🇳 #DualityBio announced a collaboration with $AZN to jointly explore a clinical combination therapy involving DualityBio’s proprietary HER3-targeting ADC, DB-1310, and AstraZeneca’s third-generation EGFR inhibitor, Tagrisso® (Osimertinib).
Under the terms of the agreement, AstraZeneca will provide osimertinib to support a Phase I/II exploratory study aimed at evaluating the potential of the DB-1310 and osimertinib combination as a second-line treatment for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC).
BioNTech-backed ADC maker #DualityBio plans #IPO on #HKSE https://t.co/Sjwg8vDssz It's the 3rd IPO for 🇨🇳 biotech this year.
Pressemitteilung
#BioNTech und #DualityBio erhalten Fast-Track-Status der #FDA für #Antikörper-#Wirkstoff-#Konjugat-#Kandidat BNT324/DB-1311 bei #Prostatakrebs.
https://t.co/IKFc3tnMkP
The @US_FDA granted Fast Track designation for our #ADC candidate BNT324/DB-1311 for the treatment of castration-resistant #ProstateCancer. With this, all 3 clinical ADC candidates in our collab with #DualityBio have received Fast Track designation. https://t.co/22Gy2j7hqa
Kandidati za antitijela DB-1303 i DB-1311 imaju za cilj da unište ćelije raka na ciljani način, izbjegavajući oštećenje zdravog tkiva. Stručnjaci smatraju da se ovaj tretman bolje podnosi od kemoterapije.
#BioNTech #Njemačka #DualityBio #Kina #rak
https://t.co/eOKmmHwWZR
Njemački #BioNTech i kineski #DualityBio uspostavljaju saradnju u liječenju raka https://t.co/E6Dh4uYYok
Interessant - #BioNTech und die chinesische #DualityBio schließen globale strategische Kollaboration –> beschleunigte Entwicklung von differenzierten Antikörper-Wirkstoff-Konjugaten zur Therapie von soliden Tumoren im Fokus - https://t.co/Q4pC3upXzJ
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.5M followers
Barack Obama
@barackobama
118.9M followers
Cristiano Ronaldo
@cristiano
114.6M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.3M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90.1M followers
Taylor Swift
@taylorswift13
84M followers
Lady Gaga
@ladygaga
75.5M followers
Virat Kohli
@imvkohli
73.5M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.6M followers
Bill Gates
@billgates
65.3M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.2M followers
CNN
@cnn
61.7M followers
X
@x
60.7M followers